EA202091385A3 - Лиофилизированные составы для антидота фактора ха - Google Patents

Лиофилизированные составы для антидота фактора ха

Info

Publication number
EA202091385A3
EA202091385A3 EA202091385A EA202091385A EA202091385A3 EA 202091385 A3 EA202091385 A3 EA 202091385A3 EA 202091385 A EA202091385 A EA 202091385A EA 202091385 A EA202091385 A EA 202091385A EA 202091385 A3 EA202091385 A3 EA 202091385A3
Authority
EA
Eurasian Patent Office
Prior art keywords
factor
lyophilized formulations
antidote
fxa
lyophilization
Prior art date
Application number
EA202091385A
Other languages
English (en)
Other versions
EA202091385A2 (ru
Inventor
Дзуан Вонг
Грегори А. Сача
Фуонг М. Нгуйен
Original Assignee
Портола Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Портола Фармасьютикалз, Инк. filed Critical Портола Фармасьютикалз, Инк.
Publication of EA202091385A2 publication Critical patent/EA202091385A2/ru
Publication of EA202091385A3 publication Critical patent/EA202091385A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к растворам и способам получения лиофилизированных составов антидотов фактора Xa (fXa). Подходящий водный состав для лиофилизации может содержать антидот fXa, солюбилизирующий агент, стабилизатор и кристаллический компонент, при этом состав не разрушается во время лиофилизации.
EA202091385A 2014-08-20 2015-08-20 Лиофилизированные составы для антидота фактора ха EA202091385A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462039809P 2014-08-20 2014-08-20

Publications (2)

Publication Number Publication Date
EA202091385A2 EA202091385A2 (ru) 2021-03-31
EA202091385A3 true EA202091385A3 (ru) 2021-06-30

Family

ID=55351266

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091385A EA202091385A3 (ru) 2014-08-20 2015-08-20 Лиофилизированные составы для антидота фактора ха
EA201790415A EA036091B1 (ru) 2014-08-20 2015-08-20 ВОДНЫЕ СОСТАВЫ АНТИДОТОВ ФАКТОРА Xa (fXa) ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ УМЕНЬШЕНИЯ КРОВОТЕЧЕНИЯ И ИХ ПРИМЕНЕНИЕ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201790415A EA036091B1 (ru) 2014-08-20 2015-08-20 ВОДНЫЕ СОСТАВЫ АНТИДОТОВ ФАКТОРА Xa (fXa) ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ УМЕНЬШЕНИЯ КРОВОТЕЧЕНИЯ И ИХ ПРИМЕНЕНИЕ

Country Status (14)

Country Link
US (5) US20160237420A1 (ru)
EP (2) EP3182993B1 (ru)
JP (4) JP6742986B2 (ru)
KR (2) KR102482517B1 (ru)
CN (2) CN107073082B (ru)
AU (1) AU2015305413B2 (ru)
CA (1) CA2961739C (ru)
DK (1) DK3182993T3 (ru)
EA (2) EA202091385A3 (ru)
ES (1) ES2814157T3 (ru)
IL (2) IL250413B (ru)
SG (1) SG11201701247RA (ru)
WO (1) WO2016029061A1 (ru)
ZA (1) ZA201701764B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2414517T (pt) * 2009-03-30 2016-12-27 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
JP6742986B2 (ja) * 2014-08-20 2020-08-19 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子解毒剤の凍結乾燥製剤
CN108883160B (zh) * 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
CA3027457A1 (en) 2016-06-17 2017-12-21 Portola Pharmaceuticals, Inc. Preparation of factor xa derivatives
WO2018213151A1 (en) * 2017-05-18 2018-11-22 Merck Sharp & Dohme Corp. Pharmaceutical formulation comprising incretin-insulin conjugates
CN110760479A (zh) * 2019-05-17 2020-02-07 上海交通大学医学院附属瑞金医院 靶向血小板表达的凝血因子Xa及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2151044A1 (en) 1992-12-15 1994-06-23 Terence K. Brunck Novel inhibitors for factor xa
DK2193809T3 (en) 1999-02-22 2015-05-26 Univ Connecticut The albumin-free Factor VIII formulation
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
EP1589949B1 (en) * 2003-01-08 2008-08-13 Novartis Vaccines and Diagnostics, Inc. Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
ATE549317T1 (de) 2005-11-08 2012-03-15 Millennium Pharm Inc Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
DK3078743T3 (da) 2007-09-28 2020-08-10 Portola Pharm Inc Antidoter til faktor xa-inhibitorer og fremgangsmåder til anvendelse af disse
ATE551050T1 (de) 2008-09-03 2012-04-15 Octapharma Ag Stabilisierte zusammensetzungen für rekombinant hergestellten faktor viii
WO2010056765A2 (en) 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PT2414517T (pt) * 2009-03-30 2016-12-27 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
CN102625712B (zh) 2009-07-15 2017-07-25 博尔托拉制药公司 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US20130165459A1 (en) * 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
KR101872203B1 (ko) * 2010-04-20 2018-08-02 옥타파마 아게 약학 단백질을 위한 신규한 안정화제
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
CN103945863A (zh) * 2011-08-01 2014-07-23 爱默蕾大学 包含配体的vlp及其相关方法
US9371522B2 (en) * 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
GB201310946D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Antidote
JP6742986B2 (ja) 2014-08-20 2020-08-19 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子解毒剤の凍結乾燥製剤

Also Published As

Publication number Publication date
US11028382B2 (en) 2021-06-08
US20180320160A1 (en) 2018-11-08
KR102482517B1 (ko) 2022-12-28
US20210284986A1 (en) 2021-09-16
KR20230007550A (ko) 2023-01-12
EP3182993B1 (en) 2020-07-01
EA202091385A2 (ru) 2021-03-31
AU2015305413A1 (en) 2017-03-23
US20200299668A1 (en) 2020-09-24
CA2961739C (en) 2024-04-30
US20200299667A1 (en) 2020-09-24
IL276960A (en) 2020-10-29
JP2019206595A (ja) 2019-12-05
IL276960B (en) 2022-04-01
WO2016029061A1 (en) 2016-02-25
SG11201701247RA (en) 2017-03-30
JP2023158199A (ja) 2023-10-26
CN107073082A (zh) 2017-08-18
AU2020289768A1 (en) 2021-01-21
JP6742986B2 (ja) 2020-08-19
EA201790415A1 (ru) 2017-08-31
KR20170042776A (ko) 2017-04-19
IL250413B (en) 2020-09-30
AU2015305413B2 (en) 2020-09-24
EP3182993A1 (en) 2017-06-28
CN113171447A (zh) 2021-07-27
JP7416549B2 (ja) 2024-01-17
DK3182993T3 (da) 2020-09-21
IL250413A0 (en) 2017-03-30
EP3182993A4 (en) 2018-01-17
ES2814157T3 (es) 2021-03-26
ZA201701764B (en) 2020-10-28
CA2961739A1 (en) 2016-02-25
JP2022003101A (ja) 2022-01-11
CN107073082B (zh) 2021-04-30
CN113171447B (zh) 2024-05-17
US20160237420A1 (en) 2016-08-18
JP2017525704A (ja) 2017-09-07
EA036091B1 (ru) 2020-09-25
EP3750556A1 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
CY1123407T1 (el) Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
EA202091385A3 (ru) Лиофилизированные составы для антидота фактора ха
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201790630A1 (ru) Способы получения рибозидов
EA201591420A1 (ru) Гетероарильные соединения и их применение
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
WO2015044337A3 (en) Dry formulations of vaccines that are room temperature stable
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
EA201991798A1 (ru) Стабильные при хранении составы
EA201500931A1 (ru) Производные пиридин-4-ила
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
EA201690859A1 (ru) Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli
DK3103453T3 (da) Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201891783A1 (ru) Композиция для растворения аморфных дитиазинов и способ ее применения
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила